Literature DB >> 8806193

The role of cell adhesion molecules and proteases in tumor invasion and metastasis.

M J Bussemakers1, J A Schalken.   

Abstract

Over the past 10 years it has become apparent that invasion and metastasis are extremely complex processes; neoplastic cells must escape from the primary tumor, degrade the extracellular matrix, migrate to distant sites, arrest in the capillaries, and migrate through the basement membrane and underlying connective tissue to the metastatic site. Therefore, tumor cells must exhibit considerable flexibility in their adhesive interactions, and this is reflected in a complex and dynamic expression pattern of cell adhesion molecules, proteases, protease inhibitors, motility factors, and growth factors. Despite the recent explosion of information regarding adhesion-related molecules, questions as to their possible roles in normal tissue architecture and as to how alterations in their expression or structure may be responsible for the progression from a single malignant cell to a lethal metastatic disease need further investigation. Moreover, efforts should be made to use the obtained knowledge to contribute to improvements in the clinical management of cancer. In this review the different classes of cell adhesion molecules and proteases are summarized, with special emphasis being placed on molecules that have been shown to correlate with invasion and metastasis. Furthermore, the role of E-cadherin in cell adhesion and invasive processes is discussed in more detail, since E-cadherin may be considered promising as a candidate among cell-adhesion-regulating molecules to be used as a biomarker for malignancy. We also elaborate on the role of the catenins, which associate with and are important for the functioning of E-cadherin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806193     DOI: 10.1007/bf00186894

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  63 in total

1.  Identification of a neural alpha-catenin as a key regulator of cadherin function and multicellular organization.

Authors:  S Hirano; N Kimoto; Y Shimoyama; S Hirohashi; M Takeichi
Journal:  Cell       Date:  1992-07-24       Impact factor: 41.582

2.  Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.

Authors:  K Vleminckx; L Vakaet; M Mareel; W Fiers; F van Roy
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

Review 3.  Plasma membrane proteases: introductory remarks.

Authors:  J S Bond
Journal:  Biomed Biochim Acta       Date:  1991

Review 4.  Cell adhesion molecules: implications for a molecular histology.

Authors:  G M Edelman; K L Crossin
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

Review 5.  Cadherins: a molecular family important in selective cell-cell adhesion.

Authors:  M Takeichi
Journal:  Annu Rev Biochem       Date:  1990       Impact factor: 23.643

6.  Localization of collagenase at the basal plasma membrane of a human pancreatic carcinoma cell line.

Authors:  U M Moll; B Lane; S Zucker; K Suzuki; H Nagase
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

7.  Association of the APC tumor suppressor protein with catenins.

Authors:  L K Su; B Vogelstein; K W Kinzler
Journal:  Science       Date:  1993-12-10       Impact factor: 47.728

Review 8.  Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.

Authors:  M Schmitt; F Jänicke; N Moniwa; N Chucholowski; L Pache; H Graeff
Journal:  Biol Chem Hoppe Seyler       Date:  1992-07

Review 9.  Phylogenetic analysis of the cadherin superfamily.

Authors:  Y Pouliot
Journal:  Bioessays       Date:  1992-11       Impact factor: 4.345

10.  Regulation of keratinocyte intercellular junction organization and epidermal morphogenesis by E-cadherin.

Authors:  M J Wheelock; P J Jensen
Journal:  J Cell Biol       Date:  1992-04       Impact factor: 10.539

View more
  7 in total

1.  Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas.

Authors:  Manmeet S Ahluwalia; Carol Patton; Glen Stevens; Tanya Tekautz; Lilyana Angelov; Michael A Vogelbaum; Robert J Weil; Sam Chao; Paul Elson; John H Suh; Gene H Barnett; David M Peereboom
Journal:  J Neurooncol       Date:  2010-08-04       Impact factor: 4.130

2.  Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas.

Authors:  Elisabetta Botti; Giulia Spallone; Francesca Moretti; Barbara Marinari; Valentina Pinetti; Sergio Galanti; Paolo D'Onorio De Meo; Francesca De Nicola; Federica Ganci; Tiziana Castrignanò; Graziano Pesole; Sergio Chimenti; Luisa Guerrini; Maurizio Fanciulli; Giovanni Blandino; Michael Karin; Antonio Costanzo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-01       Impact factor: 11.205

3.  N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion withStromal cells.

Authors:  N L Tran; R B Nagle; A E Cress; R L Heimark
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

Review 4.  Regulation of E-cadherin: does hypoxia initiate the metastatic cascade?

Authors:  I R Beavon
Journal:  Mol Pathol       Date:  1999-08

5.  Toxicity effects of short term diesel exhaust particles exposure to human small airway epithelial cells (SAECs) and human lung carcinoma epithelial cells (A549).

Authors:  Mingjie Tang; Qifei Li; Lifu Xiao; Yanping Li; Judy L Jensen; Theodore G Liou; Anhong Zhou
Journal:  Toxicol Lett       Date:  2012-11-02       Impact factor: 4.372

6.  Aqueous extract of Bambusae Caulis in Taeniam inhibits PMA-induced tumor cell invasion and pulmonary metastasis: suppression of NF-κB activation through ROS signaling.

Authors:  Aeyung Kim; Minju Im; Nam-Hui Yim; Young Pil Jung; Jin Yeul Ma
Journal:  PLoS One       Date:  2013-10-28       Impact factor: 3.240

7.  Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer.

Authors:  Vishnu C Ramani; Leah Hennings; Randy S Haun
Journal:  BMC Cancer       Date:  2008-12-17       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.